MRSN — Mersana Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $36.08m
- -$45.81m
- $40.50m
- 15
- 31
- 35
- 16
Annual cashflow statement for Mersana Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -88 | -170 | -204 | -172 | -69.2 |
| Depreciation | |||||
| Non-Cash Items | 7.23 | 19.1 | 20.8 | 17.3 | 12.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.11 | 10.1 | 133 | -16 | -27.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -74.7 | -140 | -49.4 | -169 | -82.3 |
| Capital Expenditures | -0.473 | -0.648 | -2.2 | -2.17 | -0.132 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 37.5 | 0 | -151 | 122 | 11.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 37 | -0.648 | -153 | 120 | 11.4 |
| Financing Cash Flow Items | — | -0.259 | 0 | -0.15 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 230 | 63.6 | 153 | 94.7 | 4.09 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 193 | -77 | -49.1 | 45.7 | -66.8 |